Latest Breaking News On - Cancer medicine - Page 4 : comparemela.com

FDA Approves Breyanzi for Relapsed, Refractory MCL

FDA Approves Breyanzi for Relapsed, Refractory MCL
curetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from curetoday.com Daily Mail and Mail on Sunday newspapers.

United statesMichael wangMeghan gutierrezDrug administrationBristol myers squibbDivision of cancer medicineUniversity of texas md anderson cancer centerLymphoma research foundationDepartment of lymphomaPuddin clarke endowed professorCancer medicineCancer center

Marriage Boosts Cancer Survival More Than Chemo

Marriage Boosts Cancer Survival More Than Chemo
newsmax.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newsmax.com Daily Mail and Mail on Sunday newspapers.

Daniel landauDaily mailClinical oncologyCancer medicineSouth carolina based

Dr Halperin on the FDA Approval of Lutetium Lu 177 Dotatate for Pediatric SSTR+ GEP-NETs

Dr Halperin on the FDA Approval of Lutetium Lu 177 Dotatate for Pediatric SSTR+ GEP-NETs
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

United statesDanielm halperinDivision of cancer medicineDepartment of gastrointestinal medical oncologyUniversity of texas md anderson cancer centerGastrointestinal medical oncologyCancer medicineCancer center

Marriage may be more likely to save you from cancer than CHEMO

A study re-emerged this week claiming that married cancer patients are up to 33 percent less likely to die than those who are single, and marriage was up to 20 percent more effective than chemo.

South carolinaUnited statesDaniel landauBrad wilcoxSteve sailerRichard hananiaUniversity of virginiaMesothelioma center at asbestosMesothelioma centerClinical oncologyCancer medicine

Dr Ravin Ratan on Advancing Sarcoma Care at ASCO 2024

In this interview ahead of the 2024 American Society of Clinical Oncology annual meeting (ASCO), Ravin Ratan, MD, MEd, The University of Texas MD Anderson Cancer Center, discusses study data he is excited to hear more about on the combination of trabectedin and low-dose irinotecan for relapsed/refractory Ewing sarcoma.

United statesMccormick placeDepartment of sarcoma medical oncologyAmerican society of clinical oncologyUniversity of texas md anderson cancer centerDivision of cancer medicineOrthopaedic centerClinical oncologySarcoma oral abstract sessionAmerican journalRavin ratanSarcoma medical oncologyCancer medicineCancer center